Glutamate Inhibitors in Glioblastoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Glioblastoma
Interventions
DRUG

Gabapentin

Weekly dose escalations over 4 weeks of daily 3 x 300 mg up to 3 x 1200 mg

DRUG

Sulfasalazine

Weekly dose escalations over 3 weeks of daily 3 x 500 mg up to 3 x 1500 mg

DRUG

Memantine

Weekly dose escalations over 4 weeks of daily 1 x 5-20 mg

DRUG

Temozolomide

Concomitant with radiotherapy at 75 mg/m2 daily followed by maintenance 150-200 mg/m2 on 5/28 days

RADIATION

Radiotherapy

30 x 2 Gy involved field radiotherapy with concomitant temozolomide

Trial Locations (1)

8090

RECRUITING

University Hospital Zurich, Zurich

All Listed Sponsors
collaborator

Swiss National Science Foundation

OTHER

lead

University of Zurich

OTHER